Agenus Inc. — Form 10-K summary
Reporting period: Fiscal year ended December 31, 2022. Although the request identifies 2022 Q4, this filing is an annual report; the supplied text does not provide standalone fourth-quarter financial results. Filed March 16, 2023.
Business context
Agenus is a clinical-stage biotechnology company focused on immuno-oncology, with antibody programs, cell therapies through majority-owned MiNK Therapeutics, and vaccine adjuvants through SaponiQx. Botensilimab, a next-generation CTLA-4 antibody, is its lead proprietary program, being studied alone and in combinations. The company also earns service, collaboration, milestone, and royalty-related revenue; it has no products approved for commercial sale in the United States.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Total revenue | $98.0 million | $295.7 million |
| Operating income (loss) | $(179.4) million | $25.7 million |
| Net loss | $(230.7) million | $(28.7) million |
| Net cash from (used in) operating activities | $(175.4) million | $10.1 million |
| Research and development expense | $186.7 million | $178.6 million |
| General and administrative expense | $81.0 million | $76.4 million |
- Revenue declined primarily because FY 2021 included $220.0 million of BMS license and milestone revenue. FY 2022 included $17.0 million of R&D revenue, $25.3 million in royalty sales milestone revenue, and $45.3 million of non-cash royalty revenue associated with the previously monetized GSK royalty stream.
- The $45.3 million of non-cash royalty revenue is not equivalent to cash available to Agenus: GSK royalties are directed to HCR under the royalty purchase arrangement. Agenus also recorded $62.7 million of related non-cash interest expense. The royalty-related liability was $271.3 million net at year-end.
- Cash, cash equivalents, and short-term investments totaled $193.4 million at December 31, 2022, down $113.6 million from a year earlier. Total current assets were $213.1 million and current liabilities $189.0 million.
- Debt principal was approximately $13.6 million. The $13.0 million subordinated notes bear 8% interest and were extended to February 2025. Reported total stockholders’ equity was a deficit of $54.9 million.
- Operating lease commitments were $129.3 million and finance lease commitments $27.7 million in the contractual-obligations table. The Emeryville manufacturing facility is a significant ongoing investment.
- FY 2022 included a $16.3 million gain on property sales and a $6.1 million impairment loss on lease right-of-use assets, among other non-operating items. These items affected reported results and are not recurring operating revenue.
Material changes, outlook, and risks
- Management said year-end resources were expected to cover liquidity needs for more than one year from issuance of the financial statements, while also stating that additional capital will be needed to complete clinical development. Management may reduce spending, capital expenditures, or program scope and identifies partnerships, milestones, asset sales, project financing, and equity issuance as potential funding sources.
- Agenus sold approximately 45.1 million shares through its at-the-market program in 2022, generating $99.2 million net. It sold another approximately 26.3 million shares for $48.6 million net from January 1 through March 10, 2023. This provides liquidity but dilutes existing shareholders. The company reported 332.5 million common shares outstanding as of March 15, 2023.
- R&D expense rose 5% and G&A expense rose 6% year over year. The company said it reduced expenses by approximately 20% in May 2022 to improve efficiency and focus on priority programs; the reported annual expense increases reflect program and subsidiary spending, among other factors.
- Botensilimab/balstilimab studies reported encouraging response data in treatment-resistant cancers. The filing also cites data reported in January 2023, after the fiscal year-end. These results are interim or preliminary, may change as data mature, and do not establish approval or commercial success.
- Balstilimab’s U.S. monotherapy BLA was withdrawn in 2021 at FDA’s recommendation after pembrolizumab received full approval; Agenus also stopped pursuing U.S. registration of balstilimab plus zalifrelimab for second-line cervical cancer. Development of balstilimab combinations, including with botensilimab, continues.
- Key risks include clinical efficacy and safety uncertainty, trial enrollment and execution, regulatory approval, manufacturing scale-up and facility qualification, intense competition, dependence on partners, and the need for future financing. Agenus also disclosed the March 2023 SVB closure and noted potential risks to access to funds at financial institutions; it reported no known material deterioration in its cash portfolio at the time of filing.
- KPMG issued an unqualified opinion on the financial statements and internal controls. Going-concern liquidity analysis was identified as a critical audit matter, including auditor scrutiny of the feasibility of management’s spending plans.
Important facts for investors to verify
- How mature and reproducible are botensilimab’s clinical results, and what are the timing, safety, enrollment, and regulatory requirements for the ongoing trials?
- How quickly is cash being used, what financing is needed beyond management’s stated liquidity horizon, and what dilution could result from continued ATM sales?
- How much of reported revenue represents cash retained by Agenus versus non-cash royalty accounting, and how will the HCR liability and related interest evolve?
- What cash is available at Agenus versus MiNK, given MiNK’s funds are not freely accessible to the parent?
- What are the cost, completion, and qualification risks of the Emeryville manufacturing facility, and how dependent are programs on collaborators’ decisions and milestones?